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Combination therapy with ACE inhibitors and angiotensin
II receptor blockers to halt progression of chronic renal dis-
ease: Pathophysiology and indications. It is no a secret that
we are confronted by an alarmingly increasing number of pa-
tients with progressive renal disease. There is ample evidence
for the notion that angiotensin II (Ang II) is a major culprit
in progression. The vasopeptide Ang II turned out to have
also multiple nonhemodynamic pathophysiologic actions on the
kidney, including proinflammatory and profibrogenic effects.
Diverse complex Ang II generating systems have been identi-
fied, including specifically local tissue-specific renin-angiotensin
systems (RAS). For example, proximal tubular cells have all
components required for a functional RAS capable of synthe-
sizing Ang II. On the other hand, Ang II is not the only ef-
fector of the RAS and other peptides generated by the RAS
influence renal function and structure as well. Moreover, the
discoveries that Ang II can be generated by enzymes other
than angiotensin-converting enzyme (ACE) and that Ang II and
other RAS derived peptides bind to various receptors with dif-
ferent functional consequences have further added to the com-
plexity of this system. Several major clinical trials have clearly
shown that ACE inhibitor treatment slows the progression of re-
nal diseases, including in diabetic nephropathy. Well-controlled
studies demonstrated that this effect is in part independent of
blood pressure control. More recently, with Ang II type 1 re-
ceptor (AT1) receptor antagonists a similarly protective effect
on renal function was seen in patients with type 2 diabetes.
Neither ACE inhibitor treatment nor AT1 receptor blockade
completely abrogate progression of renal disease. A recently
introduced novel therapeutic approach is combination treat-
ment comprising both ACE inhibitor and AT1 receptor an-
tagonists. The rationale for this approach is based on several
considerations. Small-scale clinical studies, mainly of crossover
design, documented that combination therapy is more potent
in reducing proteinuria in patients with different chronic re-
nal diseases. Blood pressure as an important confounder was,
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however, significantly lower in the majority of this studies in
the combination treatment arms compared to the respective
monotherapies. In a recent prospective study Japanese authors
avoided this confounder and demonstrated that combination
therapy reduced hard end-points (end stage renal failure or
doubling of serum creatinine concentration) by 50% compared
to the respective monotherapies. This effect could not be ex-
plained by a more pronounced reduction of blood pressure in
the combination therapy group. Although these results are en-
couraging, administration of combination therapy should be re-
served currently to special high risk groups. Further studies are
necessary to confirm these promising results. It is possible that
combination therapy may increase the risk of hyperkalemia,
particularly when with coadministered with medications such as
nonsteroidal anti-inflammatory drugs (NSAIDs) or spironolac-
tone. In our opinion patients with proteinuria >1 g/day despite
optimal blood pressure control under RAS-blocking monother-
apy are a high-risk group which will presumably benefit from
combination therapy.
One of the major challenges in nephrology is the ex-
ponentially growing number of patients developing ter-
minal renal failure. It is now well-appreciated that the
majority of these patients have a chronic decline of re-
nal function over years before dialysis is required. This
nonspecific process continues even when the initial in-
sult is no longer present and has been called progres-
sion of chronic renal disease [1]. Regardless of the pri-
mary cause, the common underlying histologic lesions
comprise tubulointerstitial fibrosis, tubular atrophy, and
glomerulosclerosis [1, 2]. Clinical studies have provided
ample evidence that hypertension and the degree pro-
teinuria are the most important factors influencing pro-
gression [3]. The role of these mechanisms in progres-
sion of chronic nephropathy has been reviewed elsewhere
[3]. Angiotensin II (Ang II) mediates both hemodynamic
changes and renal growth suggesting that these processes
are intimately connected. Both are thought to contribute
to progression [4]. As summarized in Table 1, the non-
hemodynamic actions of Ang II include stimulation of
tubular transport, facilitation of proteinuria by modifying
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Table 1. Effects of angiotensin II (Ang II) implicated in the progression of renal disease
Vasoconstriction
Expression of further vasoconstrictors (endothelins) and inhibition of vasodilators (nitric oxide, atrial natriuretic peptides)
Mediation of glomerular hyperfiltration/glomerular hypertension
Increased proteinuria by hemodynamic and nonhemodynamic effects (as modification of glomerular basement membrane characteristics,
suppression of nephrin)
Increased tubular uptake of proteins
Stimulation or inhibition of tubular transporters (depending on the dose)
Induction of profibrogenic cytokines [transforming growth factor-b (TGF-b)]
Stimulation of glomerular and tubular growth (proliferation, hypertrophy)
Induction of proinflammatory cytokines and chemokines [interleukin 6, interleukin 8, osteopontin, regulated upon activation, normal T-cell
expressed and secreted (RANTES), and monocyte chemoattractant protein-1 (MCP-1)]
Generation of reactive oxygen species, activation of nuclear factor-kappaB (NF-jB)
Stimulation of fibroblasts proliferation
Facilitation of lymphocyte proliferation
Up-regulation of adherence molecules on endothelial cells
Up-regulation of specific lipoprotein receptors
structure and function of the glomerular ultrafiltration
barrier, induction of proinflammatory as well as profi-
brogenic cytokines such as transforming growth factor-b
(TGF-b) (for review see [4]). Therefore, antagonizing
these effects of Ang II is a key component of therapeutic
strategies to halt progression.
The efficacy of angiotensin-converting enzyme (ACE)
inhibitors to lower blood pressure has been known since
the middle 1970s [5]. Back then a normal kidney func-
tion was often considered a prerequisite for the treat-
ment with ACE inhibitors. This na¨ive view was changed
forever by the seminal studies of Anderson, Rennke, and
Brenner [6]. They documented that an ACE inhibitor re-
duced proteinuria and limited glomerular injury in the
rat renal ablation model. The renoprotective action of
ACE inhibitors was subsequently shown in human stud-
ies as well, initially in type 1 diabetes [7], but subsequently
also in nondiabetic renal disease [8]. There is now limited
evidence from experimental [9] as well as from clinical
studies [3] that ACE inhibitor treatment may even cause
regression of renal disease.
The development of specific competitive nonpeptide
Ang II receptor antagonists of the imidazole-5-acetic acid
compound group provided an investigative breakthrough
[10]. In 1990, losartan, the prototype Ang II type 1 recep-
tor (AT1) receptor antagonist, was the first orally active
nonpeptide Ang II receptor antagonist to be used in hu-
mans [10]. On the other hand, the development of sub-
stances such as PD123177 which had little, if any, effect on
the AT1 receptor but specifically blocked the AT2 recep-
tor confirmed the long-known heterogeneity of Ang II
receptors [10]. The AT1 receptor has been cloned from
vascular smooth muscle cells and adrenal glands (for re-
view see [4]). More recently, the AT2 receptor has been
cloned as well and there is even preliminary evidence for
further Ang II receptor subtypes [4]. In some [11], but not
all [1, 13], experimental models of renal damage AT1 re-
ceptor antagonists prevented progression of renal injury
to a similar degree as ACE inhibitors. Initial studies in pa-
tients with essential hypertension suggested that losartan
has virtually no side-effects and similar antihypertensive
potency as ACE inhibitors [14]. Short-term clinical trials
with a crossover design have shown identical antiprotein-
uric effects of AT1 blockers and ACE inhibitors in pro-
teinuric patients with various chronic renal diseases [15].
At least five large clinical studies provide now evidence
that AT1 receptor antagonists slow the rate of progres-
sion in patients with diabetic type 2 nephropathy [16–20].
Yet, neither monotherapy with an ACE inhibitor nor with
an AT1 receptor antagonist is able to completely prevent
end-stage renal disease (ESRD).
Recently the concept has been introduced that com-
bination therapy (i.e., coadministration of an ACE in-
hibitor and an AT1 receptor antagonist) is superior to
the respective monotherapies. Although such combina-
tion may at first sight seem redundant, a sound pathophys-
iologic rationale can be offered to explain the superiority
of combination therapy. In the following, we discuss the
pathophysiologic background and the clinical data. We
then provide arguments why combination therapy with
licensed doses of ACE inhibitors and AT1 receptor an-
tagonists may become the standard management to delay
progression in patients who have failed to respond satis-
factorily to the respective monotherapies.
THE RENIN-ANGIOTENSIN SYSTEM (RAS) IS
MUCH MORE COMPLEX THAN WE THOUGHT
IN THE PAST
Traditionally, the RAS has been considered as an
endocrine system. In this view, the glycoprotein an-
giotensinogen, produced in the liver, is cleaved by rennin,
which is released from renal juxtaglomerular cells. Thus,
angiotensin I is generated, which in turn is converted by
the high ACE activity of the lungs into the active sub-
stance Ang II.
Recently, is has become apparent that the system is
much more complex. Genetic polymorphisms for various
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components of the RAS have been described [21]. The
results are controversial, presumably in part explained by
the different ethnic backgrounds of the study populations,
and the controversies are far from being settled. Never-
theless, overexpression of the ACE gene in mice with
three copies of the gene and experimentally induced dia-
betes aggravates nephropathy indicating that the overall
activity of ACE, systemically and perhaps even more im-
portant locally, could be important at least under patho-
physiologic conditions [22].
Accumulating evidence suggests that local angi-
otensin-generating systems exist, in various tissues,
among others in the kidney, which operate independently
of their systemic counterpart (reviewed in [4]). Such local
tissue specific RASs have also been found in the vascular
wall, brain, adrenal gland, testis, and ovary. In the kid-
ney, a complete local RAS, including all its components,
has been localized in proximal tubular cells. Micropunc-
ture experiments demonstrated that proximal tubular
fluid contains Ang II concentrations in the nanomolar
range compared with picomolar concentrations in the
systemic circulation [23]. Moreover, using microdialysis
techniques Ang II concentrations in the nanomolar range
were measured in the renal interstitial fluid. These studies
suggest that tubular cells generate Ang II [24, 25]. It re-
mains, however, controversial whether Ang II is actually
produced in the intracellular compartment. It is possible
that angiotensinogen is secreted by tubular cells and that
Ang II is subsequently formed in the extracellular space
by the enzymatic machinery of the ACE containing brush
border membrane in the extracellular space. In line with
this hypothesis, tubular cells are known to secrete an-
giotensinogen into the urine [26]. Urinary angiotensino-
gen, but not urinary Ang II, appears to reflect activation
of the intrarenal RAS [26]. A positive autocrine feed-
back system exists in proximal tubular cells in that Ang
II further stimulates angiotensinogen synthesis [27, 28].
Angiotensinogen delivered into the tubular fluid might
be processed by more distal cells. Indeed, recent evidence
suggests that Ang II modulates the activity of the sodium
channel in distal tubules [29]. Local production of Ang II
at these sites is obviously independent from the regula-
tion of the systemic RAS [28]. Renal injury activates the
local RAS directly and indirectly [4]. For example, 1,25-
dihydroxyvitamin D3 is a negative regulator of the RAS
and suppresses renin expression [30]. A reduction in 1,25-
dihydroxyvitamin D3, as occurs early in renal failure, will
allow the local RAS to escape from feedback inhibition
stimulating renin transcription and leading to a local in-
crease in ANG II [30]. Proteinuria is a potent stimulator
of the RAS in proximal tubular cells [31]. It is obvious
that the local tubular RAS may interact with the sys-
temic RAS at different levels [33]. For example, renin or
angiotensinogen could be taken up from the circulation
thus affecting the local generation of Ang II. Vascular en-
dothelium could convert Ang I to Ang II, although it does
not express renin. Studies in perfused hindlimbs of rats
convincingly demonstrated that Ang II, locally formed in
the vasculature, contributes to elevated blood pressure
in renal failure despite suppressed plasma Ang II [32].
Furthermore, renin is taken up from the circulation into
endothelial cells and contributes to local formation of
Ang I demonstrating interaction between local and sys-
temic components of the RAS [32]. Ang II itself could be
taken up into the renal interstitium from the circulation
via AT1 receptors [33].
DOES THE ACTIVITY OF THE SYSTEMIC AND
THE LOCAL RAS CHANGE IN PARALLEL?
Particularly important is the observation that systemic
administration of an ACE inhibitor results in almost com-
plete inhibition of systemic Ang II formation, but affects
intrarenal Ang II production little or not at all [34]. Fur-
thermore, intrarenal Ang II is regionally compartmental-
ized. For instance, overall concentrations are higher in the
medulla compared with the cortex [35]. Intact Ang II is
present in intracellular compartments (endosomes). It is
derived from receptor-mediated endocytosis subsequent
to binding of Ang II to its putative receptor [35]. This
could be an important mechanism because it has been
demonstrated that Ang II may penetrate into adjacent
cells by diffusion and may be even translocate into the nu-
cleus where it directly regulates gene transcription [36].
Specific Ang II receptors have been localized on the nu-
clear membrane [4].
IS ACE THE ONLY ENZYME INVOLVED IN THE
GENERATION OF ANG II?
The traditional view held that ACE is the only en-
zyme capable of Ang II formation. This paradigm has
recently been challenged [37]. Cardiovascular tissues ex-
press Ang II–generating enzymes other than ACE [37,
38]. One important example is the serine protease chy-
mase. ACE inhibitors do not inhibit chymase activity,
but today this enzyme can be inhibited by chymase-
specific inhibitors. This allows us to differentiate between
chymase-dependent and ACE-dependent Ang II forma-
tion [37]. It has been shown that more than 80% of Ang
II formation in the heart and more than 60% in vessels
may be due to chymase [37]. Specific chymase inhibitors
attenuated cardiac fibrosis and Ang II–mediated TGF-b
expression in animal models [38]. Since chymase is chiefly
synthesized in mast cells, an accumulation of these cells
in atherosclerotic plaques accounts for ACE independent
formation of Ang II in atherosclerotic tissue [39].
Is chymase present in the kidney? A recent study
demonstrated expression of chymase in the kidney of dia-
betic patients [40]. Up-regulation of chymase, in contrast
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to ACE expression, was closely correlated with the pres-
ence of hypertension and extracellular matrix deposition
[40]. This study provides direct evidence that chymase
represents an alternative pathway for intrarenal Ang II
formation at least in the diabetic kidney. In this context it
is of interest that renal Ang II generation is not attenuated
in ACE knockout (−/−) compared to the ACE+/+ wild-
type mice [41]. Renal chymase activity was increased in
ACE−/− animals suggesting that that this enzyme could
easily compensate for the lack of ACE in mediating Ang
II generation [41]. In addition to ACE and chymase, other
enzymes, including chymostatin-sensitive angiotensin II-
generating enzyme (CAGE) have been postulated to play
a, presumably minor, role in Ang II generation [42]. It
has been calculated that renal Ang II formation from en-
zymes other than ACE and chymase contributes <2%
of total tissue Aang II [42], but the proportion might be
drastically altered in diseased tissue.
Durvasula et al [43] demonstrated in cultured
podocytes that mechanical strain increases ANG II syn-
thesis. This interesting mechanism may link elevated pres-
sure gradient across the capillary wall that occurs in
remnant nephrons after loss of renal tissue, with alter-
ation in function and structure of podocytes. Importantly,
preincubation with an ACE inhibitor did not block the
stretch-induced increase in Ang II indicating that gener-
ation occurs by other enzymes.
Another fascinating aspect of ACE has recently been
discovered. Kohlstedt et al [44] provided convincing ev-
idence for a novel function for ACE as a key signal
transduction molecule. Using endothelial cells, Kohlst-
edt et al demonstrated that the ACE inhibitors ramiprilat
and perindoprilat increase CK2-mediated phosphoryla-
tion of serine1270. Furthermore, ACE inhibitor treatment
also increased the activity of N-terminal kinase (JNK)
in endothelial cells [44]. These provocative findings indi-
cate that ACE inhibitors may mediate cellular function
by “outside-in” signaling directly through ACE, an effect
totally independent of the generation of Ang II.
ARE ALL DETRIMENTAL ACTIONS OF ANG II
MEDIATED BY THE AT1 RECEPTOR?
Two main Ang II receptors (AT1 and AT2) exist which
are differentially expressed within in the kidney [45].
Both receptors have been cloned. They have the con-
figuration of a seven-transmembrane receptor, but share
only around 30% homology on the protein level. Phar-
macologic evidence suggests that there may be additional
binding sites for Ang II, at least in certain species, but
those putative receptors have not yet been identified
on a molecular level [45]. AT1 receptors are coupled
to heterotrimeric G proteins and engage various sig-
nal transduction pathways, including activation of phos-
pholipases, inhibition of adenylate cyclase, stimulation
of tyrosine phosphorylation, and other second messen-
ger pathways [45]. Whether the AT2 receptor associates
with G proteins is controversial [46]. A number of stud-
ies have indicated that activation of AT2 receptors leads
to an increase in intracellular protein phosphatase ac-
tivity [46]. Depending on the cell type, either tyrosine
or serine/threonine phosphatases are stimulated. Both
AT1 and AT2 receptors are developmentally regulated,
but the AT2 receptor is much more abundant in the fe-
tal kidney. Throughout nephrogenesis, the AT2 recep-
tor is mainly expressed in undifferentiated mesenchyme.
It is down-regulated after birth. AT1 receptors are ini-
tially localized in the nephrogenic cortex and developing
glomeruli, proximal tubules, and vessels. During matu-
ration of the kidney, AT1 receptor expression becomes
more abundant.
AT1 receptor expression is induced by a variety of stim-
uli, including hypercholesteremia and changes in osmo-
larity, but is down-regulated by high Ang II concentra-
tions [45]. In contrast, AT2 receptors are induced by tissue
injury but are not down-regulated by high Ang II [46].
Specifically, AT2 receptors are reexpressed in the kid-
ney during renal injury and remodeling of nephrons [46].
Thus, in pathophysiologic situations when tissue injury
has occurred and when the local RAS is activated Ang II
may preferentially bind to up-regulated AT2 receptors.
Almost all classic Ang II–associated functions such
as vasoconstriction, aldosterone release, stimulation of
tubular transport, proinflammatory effects as well as
profibrogenic and growth stimulatory actions are medi-
ated by the AT1 receptors [4]. The function of the AT2
receptor is less clear, but is has been proposed that acti-
vation of this receptor antagonizes those functions which
are mediated by the AT1 receptor, providing negative
feedback control. Along this line, it has been shown that
activation of the AT2 receptors decreases blood pressure
through release of nitric oxide, inhibits growth and in-
duces differentiation, and even mediates apoptosis [46,
47]. Recent evidence, however, indicates that cell hyper-
trophy and proinflammatory effects are also transduced
by AT2 receptor activation under certain conditions [48–
51].
IS STIMULATION OF THE AT2 RECEPTOR
BENEFICIAL OR INJURIOUS?
Treatment with an ACE inhibitor or an AT1 receptor
antagonist has strikingly different effects on the activa-
tion of the AT2 receptor. ACE inhibition leads, at least
initially, to a decrease in Ang II formation so that less
Ang II binds to AT1 as well as AT2 receptors. In contrast,
AT1 receptor blockade does not reduce, and actually in-
creases, the concentration of Ang II (Fig. 1). This excess of
Ang II will then bind to and activate AT2 receptors. In the
past it had been assumed that activation of AT2 receptors
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Fig. 1. Differences between angiotensin II type 1 (AT1) receptor an-
tagonists and angiotensin-converting enzyme (ACE) inhibitors. Since
AT1 receptor blockers increase the local angiotensin II (Ang II) con-
centration (interruption of negative feedback at the juxtaglomerular
apparatus), Ang II could either bind to AT2 receptors or, after conver-
sion to Ang IV, interact with AT4 receptors. Obviously, binding of excess
Ang II to AT2 and AT4 receptors is not antagonized by AT1 blockers. In
contrast, inhibition of ACE reduces the Ang II concentrations resulting
in less agonistic stimulation of both for AT1 and AT2 receptors. Fur-
thermore, ACE inhibitor increase bradykinin levels through inhibition
of its breakdown by the kinase activity of ACE.
is exclusively beneficial [10]. Nevertheless, evidence has
recently accumulated which clearly suggests that AT2 re-
ceptors may mediate adverse effects. The activated AT2
receptor stimulates proinflammatory pathways by induc-
tion of nuclear factor-kappaB (NF-jB) [49, 50]. Further
evidence for potentially adverse effects of AT2 receptor
stimulation is provided by in vivo studies demonstrating
that AT2 receptor blockers exhibit anti-inflammatory ef-
fects in models of renal injury and are associated with
attenuation of renal damage [51].
A further difference between the effects of ACE in-
hibition and AT1 receptor blockade concerns the con-
centration of bradykinin. ACE inhibition attenuates
the breakdown of bradykinin, a vasodilatory peptide
(Fig. 1). Experimental data argue against a major role
of bradykinin in the renoprotective action of ACE in-
hibitors. Using specific bradykinin receptor blockers, it
has been shown in animal models of chronic renal dis-
ease that the protective effects of ACE inhibitors are due
to reduced Ang II and not increased bradykinin concen-
trations [52, 53].
A further difference between ACE inhibitors and AT1
receptor blockers concerns the plasma concentration of
the tetrapeptide acetyl-seryl-aspartyl-lysyl-proline a nat-
ural substrate for ACE which increases after ACE inhi-
bition. It has recently been shown that it interferes with
the development of cardiac fibrosis [54] and possibly also
renal fibrosis.
To introduce further complexity, a specific extracellu-
lar receptor for renin with no homology to any known
membrane protein has been identified on mesangial and
vascular smooth muscle cells [55]. Binding of renin to this
receptor leads to activation of mitogen-activated protein
(MAP) kinases and also increased intracellular efficiency
of angiotensinogen cleavage to Ang I [55]. This finding
raises the possibility that very high local concentrations
of Ang II may be build up in the vicinity of this receptor.
The role of renin receptors in patients with renal disease
is currently unknown.
METABOLISM OF ANG II AND GENERATION
OF ALTERNATIVE PEPTIDES
So far we have only discussed generation and action
of Ang II. How about breakdown of Ang II? Ang II
is metabolized by peptidases, such as aminopeptidase A
(APA) [56], into Ang III and further into Ang IV. Ang
IV binds to a specific receptor named AT4 [57]. This re-
ceptor is widely expressed in the kidney including en-
dothelial cells, and proximal and convoluted tubules [57].
Recent evidence suggests that this receptor may be iden-
tical with the enzyme insulin-regulated aminopeptidase
[58]. Ang IV stimulates plasminogen activator inhibitor-1
(PAI-1) expression in proximal tubular and endothelial
cells through AT4 receptors [57, 59]. Since PAI-1 reduces
extracellular matrix turnover, Ang IV may contribute
to renal fibrosis independently of activation of AT1 and
AT2 receptors. Moreover, Ang IV generating enzymes
are up-regulated in conditions of renal injury associated
with high Ang II concentrations [56], presumably shift-
ing more Ang II into the degradation pathway to Ang IV.
Other effects of Ang IV are release of nitric oxide and
phosphorylation of focal adhesion kinase [60, 61].
Another bioactive peptide derived from the RAS is
Ang 1-7. Interestingly, Ang 1-7 has properties oppos-
ing the effects of Ang II [62]. For example, Ang 1-7
has antihypertensive effects by stimulating the release
of vasodilator prostaglandins and nitric oxide [62]. Fur-
thermore, Ang 1-7 inhibits proliferation of cells and op-
poses the growth stimulatory effects of Ang II [62]. Some
of these effects may be explained by Ang 1-7–induced
down-regulation of AT1 receptors [63]. Recent evidence
suggests that ANG 1-7 is the endogenous ligand for a
G protein–coupled receptor encoded by the mas proto-
oncogene [63]. Ang 1-7 is formed by a two step process
involving Ang 1-9 as an intermediate from Ang I, bypass-
ing the requisite production of Ang II (Fig. 2). It has also
recently been shown that Ang 1-7 blocks interconversion
of Ang I to Ang II mediated by tissue ACE.
IS ACE THE ONLY CARBOXYPEPTIDASE
ACTING ON ANG I?
A novel enzyme with similarities to ACE has recently
been identified and called ACE2 [65]. ACE2 is expressed
predominantly in vascular endothelial cells, including
those of the kidney [66]. ACE and ACE2 have different
actions. Whereas the “classic” ACE converts Ang I to the
octapeptide Ang II, ACE2 cleaves one amino acid less off
from Ang I so that Ang 1-9 is formed [65]. Ang 1-9 itself
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Fig. 2. Overview of angiotensin-converting enzyme (ACE) and ACE2
functions. The “classic” ACE1 leads to the formation of the octapeptide
angiotensin II that is further metabolized by aminopeptidase A into an-
giotensin III and finally angiotensin IV. The recently discovered ACE2
enzyme cleaves one amino acid less, forming angiotensin 1-9. This in-
termediate without known function is subsequently converted by the
“classic” ACE inhibition into angiotensin 1-7. The effects of angiotensin
1-7 are opposite to those of angiotensin II such as vasodilatation and
also down-regulates angiotensin II type 1 (AT1) receptors. It has been
hypothesized that it is an endogenous antagonist of angiotensin II. Some
data suggest that ACE2 is influenced by ACE inhibitors. ACE inhibi-
tion causes less formation of less angiotensin II but possibly also less
conversion of angiotensin 1-9 to angiotensin 1-7. The result would be
less antagonism to the activity of angiotensin II by reduced availability
of its endogenous antagonist.
has no known biologic activity. In a second step it can be
further converted to Ang 1-7, however, by the “classic”
ACE. Thus, it has been be suggested that up-regulation
of ACE2 counteracts the function of Ang II, because
more Ang I is shifted into the Ang 1-7 forming path-
way which mediates biologic effects opposite to those of
Ang II [65]. Interestingly, ACE2 knockout mice exhibit
severely impaired cardiac function and up-regulation of
hypoxia-inducible genes, but have normal blood pressure
[65]. Although ACE2 is not directly influenced by an ACE
inhibitor, these drugs may indirectly diminish the produc-
tion of Ang 1-7, because the second conversion step of
this pathway (i.e., from Ang 1-9 to Ang 1-7, depends on
the “classic” ACE (Fig. 2). In the kidney, ACE2 is pref-
erentially expressed in renal tubules and this expression
is reduced in diabetic rats [66]. Such altered expression
could further increase tubular Ang II because more sub-
strate is provided for ACE [66].
WHAT IS THE CLINICAL EVIDENCE FOR A
RENOPROTECTIVE ACTION OF ACE
INHIBITORS?
The first trial documenting the renoprotective action
of ACE inhibitors compared captopril with placebo in
type 1 diabetic patients with advanced nephropathy [7].
Captopril treatment reduced the combined endpoints of
death, dialysis, and transplantation by 50%. Importantly,
the reduction of the risk was statistically significant by
multivariate analysis even when the minor blood pressure
difference between the groups was taken into account
[7]. In the “Angiotensin-Converting Enzyme Inhibition
in Progressive Renal Insufficiency” (AIPRI) trial patients
with renal insufficiency caused by various kidney diseases
received 10 mg/day benazepril or placebo [67]. In the be-
nazepril group the risk of reaching a renal end point (i.e.,
doubling of serum creatinine or dialysis) was reduced by
more than 50%. Diastolic blood pressure was somewhat
lower in treated patients than in the placebo group so
that it remained undecided whether the renoprotective
effect was caused by better blood pressure control. In
the “Ramipril Efficacy in Nephropathy Study” (REIN)
patients mainly with chronic nondiabetic renal disease
were categorized according to baseline proteinuria, and
assigned either to ramipril or placebo on top of conven-
tional antihypertensive therapy targeted to achieve di-
astolic blood pressure values <90 mm Hg [68, 69]. In
patients with proteinuria of 1 to 3 g/day, progression to
ESRD was significantly less frequent in the ramipril arm
and so was progression to nephrotic proteinuria. Impor-
tantly, blood pressure was titrated to identical values in
the ramipril and placebo groups [69]. In patients with pro-
teinuria >3.5 g/day the REIN study was stopped at the
second interim analysis, since the difference in decline
in glomerular filtration rate (GFR) between the ramipril
and placebo groups was highly significant. Ramipril treat-
ment reduced the combined risk of doubling of serum cre-
atinine or end-stage renal failure by half [69]. The REIN
core and follow-up studies offer convincing evidence that
the tendency of GFR to decline in chronic renal disease
can be effectively halted [8, 70]. A recent meta-analysis
indicated that antihypertensive regimens which include
ACE inhibitors are superior to regimens without ACE
inhibitors in delaying the progression of disease across a
spectrum of renal diseases [71]. It was concluded that this
beneficial effect of ACE inhibition is independent of the
decrease in blood pressure and urinary protein excretion
[71].
In a small prospective crossover trial Lods et al [72] in-
vestigated the effect of an ACE inhibitor and an AT1 re-
ceptor antagonist on the activities of metalloproteinases
(MMPs) in patients with glomerulonephritis [72]. MMPs
are enzymes involved in the turnover of extracellular ma-
trix proteins and their activity is increased in different
models of renal inflammation. ACE inhibitor treatment,
but not irbesartan reduced MMP activity in patients
with glomerulonephritis. Although it is currently unclear
whether this is beneficial for the kidney in the long run,
this study documents differences with potential patho-
physiologic relevance between ACE inhibitors and AT1
receptor antagonists [72].
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ARE AT1 RECEPTOR BLOCKERS
RENOPROTECTIVE?
Several studies provided evidence that AT1 receptor
blockers slow the progression of renal disease in pa-
tients with type 2 diabetes [16–20]. Parving et al [16]
administered the AT1 antagonist irbesartan to hyperten-
sive patients with type 2 diabetes who had early renal
damage as manifested by microalbuminuria [16]. Irbesar-
tan treatment significantly reduced proteinuria [16]. This
and other trials demonstrated that AT1 receptor block-
ers reduce microalbuminuria in patients independent of
blood pressure control and are even effective in reduc-
ing urinary albumin excretion in normotensive diabet-
ics [19, 20]. Reduction of proteinuria presumably reflects
protection against protein-induced renal injury that will
hopefully translate into preservation of kidney function
in the longer term. Two other studies used the AT1 an-
tagonists irbesartan and losartan in patients with type
2 diabetes and advanced diabetic nephropathy [17, 18].
The AT1 antagonists reduced protein excretion, and the
rate of decline in GFR causing later onset of dialysis-
dependent renal failure compared to the control medica-
tion [17, 18]. In a cohort of patients that comprised 13%
type 2 diabetics the Losartan Intervention for End Point
Reduction in Hypertension (LIFE) showed that losartan
prevented cardiovascular morbidity and death more than
did atenolol [73].
However, these studies do not answer the question
whether an AT1 antagonist is as good as, or better, or
even worse than an ACE inhibitor in delaying progres-
sion of renal disease. They also do not answer the question
whether AT1 receptor blockade will be effective in halt-
ing progression in nondiabetic renal disease. Although it
has been argued that ACE inhibitors are as renoprotec-
tive as AT1 receptor blockers, no data from clinical trials
with head-to-head comparison between ACE-inhibitors
and AT1 antagonists and hard end points are currently
available.
IS THERE CLINICAL EVIDENCE FOR
SUPERIOR BENEFIT WITH COMBINATION
THERAPY?
An overview of clinical trials investigating dual block-
ade of the RAS is shown in Table 2 [74–91]. Zoccali et al
[74] were among the first to investigate a potential ef-
fect of an AT1 receptor antagonist as add-on therapy in
11 patients treated with an ACE inhibitor. The patients
had various renal diseases, including diabetic nephropa-
thy [74]. In this pilot study, losartan caused a 30% re-
duction of proteinuria in patients who were already on
ACE inhibitors [74]. Although not significant, addition of
losartan to ongoing ACE inhibitor therapy also caused a
marked decrease in blood pressure (from 105 ± 7 mm Hg
to 98 ± 15 mm Hg mean arterial pressure). This report
exemplifies the problems with which riddled almost all
clinical studies investigating combination therapy in pa-
tients with chronic renal disease because blood pressure
was lower in the combination therapy arm. Neverthe-
less, these smaller studies contributed important data in
regard of side-effects, investigated combination therapy
of various ACE inhibitors with different AT1 receptor
antagonists, and looked at patients with heterogeneous
causes of chronic renal disease.
All studies with one exception [90] looked exclusively
at the potential reduction in proteinuria, but failed to
evaluate renal function as an outcome parameter. This
is partly explained by the short observation period (be-
tween 2 weeks and 6 months) in these studies (Table 2).
We do not deny the relevance of proteinuria. For ex-
ample, a mass screening study in more than 100,000 pa-
tients in Japan showed convincingly that proteinuria was
a strong independent predictor for the development of
end-stage renal failure [92]. How does proteinuria medi-
ate progression of renal disease? This issue has recently
been elucidated in some detail [93–98]. Proteinuria stim-
ulates protein uptake by proximal tubular cells through
megalin- and cubilin-dependent transport processes [95].
Increased protein traffic causes tubular cell dysfunc-
tion through various mechanisms, including complement-
dependent pathways and generation of oxidative stress,
among others catalyzed by iron-containing proteins. Ex-
cessive endocytosis of proteins induces local production
of proinflammatory and profibrogenic cytokines [94, 96].
The effects of Ang II and proteinuria on tubular cytokine
production are additive and presumably reinforce each
other. In the context of the present discussion it is of par-
ticular interest that proteinuria activates the local tubular
RAS [31, 97]. In the amphibian kidney is has been demon-
strated that the role of proteinuria in the genesis of tubu-
lointerstitial injury is totally independent of glomerular
damage [98]. The model allows direct exposure of “open”
nephrons with a stoma connecting the tubule with the
peritoneal cavity to proteins after intraperitoneal injec-
tion. This maneuver caused progressive focal accumula-
tion of fibrous tissue around protein-storing open, but not
around protein-free closed, tubules [98]. Nevertheless, al-
though proteinuria is a marker for progression and even a
plausibly pathophysiologically relevant culprit, it is only
a surrogate marker and not a hard end point.
Dual blockade of the RAS led in the majority of the
smaller studies summarized in Table 2 to a significant
reduction in systemic blood pressure. Since hyperten-
sion is a very important factor in progression, and since
proteinuria is also closely associated with the severity
of hypertension [99], it had remained unclear whether
the observed reduction of proteinuria was caused by the
more pronounced reduction in blood pressure with com-
bination therapy compared to the respective monothera-
pies. In other words, it had not been safely excluded that
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Table 2. Clinical studies with combination therapy
Authors (year) Reference Number of patients and disease Maximal dose Follow-up Results
Zocalli et al
(1997)
[74] 11 patients with various renal
diseases
50 mg add-on losartan 2 weeks 30% reduction in proteinuria
Russo et al
(1999)
[75] 8 patients with IgA
nephropathy
10 mg enalapril/50 mg
losartan
1 month 30% to 40% reduction in proteinuria
Ruilope et al
(2000)
[76] 108 patients with chronic renal
insufficiency
10 mg benazepril/160
mg valsartan
1 month Reduction in blood pressure and
proteinuria
Mogensen et al
(2000)
[77] 199 patients with type 2
diabetes
20 mg lisinopril/16 mg
candesartan
3 months Reduction in blood pressure and
small effect on proteinuria
Russo et al
(2001)
[78] 10 normotensive patients with
IgA nephropathy
20 mg enalapril/100 mg
losartan
2 months 40% reduction in proteinuria
Agarval et al
(200l, 2002)
[79, 80] 16 patients (12 with diabetes
and 4 with
glomerulonephritis
40 mg lisinopril/50 mg
losartan
1 month No effect on proteinuria and
reduction in transforming growth
factor-b (TGF-b) excretion
Luno et al (2001) [81] 45 patients with various
proteinuric nephropathies
20 mg lisinopril/16 mg
candesartan
6 months 30% reduction in proteinuria
independent of blood pressure
Rossing et al
(2002)
[82] 18 patients with type 2 diabetes 8 mg add-on
candesartan
2 months 25% reduction in proteinuria and
blood pressure reduction
Berger et al
(2002)
[83] 12 patients with various
chronic glomerulopathies
8 mg add-on
candesartan
2 months 30% reduction in proteinuria and
blood pressure reduction
Laverman et al
(2002)
[84] 9 patients with various chronic
glomerulonephropathies
40 mg lisinopril/100 mg
losartan
1.5 months 10% reduction in proteinuria
Jacobsen et al
(2002)
[85] 21 patients with type 1 diabetes 300 mg add-on
irbesartan
2 months 16% reduction in proteinuria and
blood pressure reduction
Kincaid-Smith
et al (2002)
[86] 60 patients with various
proteinuric nephropathies
8 mg add-on
candesartan
3 months 16% reduction in proteinuria and
blood pressure reduction
Ferrari et al
(2002)
[87] 10 patients with
glomerulonephritis
20 mg fosinopril/150 mg
irbesartan
6 weeks 40% reduction in proteinuria
independent of blood pressure
Jacobsen et al
(2003)
[88] 20 patients with type 1 diabetes 20 mg benazepril/80 mg
valsartan
2 months 15% reduction in proteinuria and
blood pressure reduction
Campbell et al
(2003)
[89] 24 patients with nondiabetic
chronic nephropathies
10 mg benazepril/80 mg
valsartan
2 months 14% reduction in proteinuria and no
significant effect on blood pressure
and creatinine clearance
Nakao et al
(2003)
[90] 263 patients with nondiabetic
renal disease
3 mg trandolapril/100
mg losartan
36 months Significant reduction in end points,
significant reduction in proteinuria,
and no difference in blood pressure
Iodice et al
(2003)
[91] 10 patients with
nonproliferative
glomerulonephropathy
20 mg ramipril/300 mg
irbesartan
2 months No additional effect by combination
therapy on proteinuria
an equal effect might have been reached by the respec-
tive monotherapies had lowering of blood pressure been
equivalent.
Equal blood pressure control was achieved in a re-
cent prospective randomized crossover study comparing
combination therapy with benazepril and valsartan with
the respective monotherapies [89]. Despite comparable
blood pressure values, combination therapy decreased
proteinuria more than ACE inhibitor or AT1 receptor
blocker alone [89].
A further problem is raised by the fact that often only
the licensed maximal doses had been used [100]. The va-
lidity of this point is illustrated by the experimental stud-
ies of Ots et al [101] and Peters, Noble, and Border [102]
which failed to show an additive effect on glomeruloscle-
rosis when maximal doses of losartan and enalapril were
combined. In pharmacologic studies it is not permitted to
draw the conclusion that two drugs have additive effects
unless maximal doses (i.e., at the plateau of the dose re-
sponse relationship) had been used. This point is all the
more important, since, as described above, the intrarenal
RAS is compartmentalized. It has been shown that doses
of ACE inhibitors higher than the maximally blood pres-
sure lowering dose are necessary to affect local Ang II
formation. Maximal doses of enalapril or losartan that
failed to cause further reduction of blood pressure nev-
ertheless further reduced TGF-b expression and renal
fibrosis in an experimental model of a mesangioprolifera-
tive glomerulonephritis [101, 102]. Yet, even at maximally
effective doses of enalapril or losartan failed to normalize
TGF-b synthesis so that it is unlikely that even complete
inhibition of the RAS, both systemic and local, would
ever completely halt progression. This point has been also
illustrated by clinical observations. In a well-controlled
study Ruggenenti et al [103] assessed forced up titration
of the ACE inhibitor lisinopril in patients with chronic
nephropathies. They found that increasing lisinopril to
maximally tolerated doses ameliorated lipid abnormali-
ties but failed to reduce proteinuria further compared to
conventional doses [103]. This finding calls for additional
interventions aiming at different targets as suggested by
Hostetter [104].
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Taking into consideration that Ang II is pivotal for
expression of TGF-b , the above findings suggest that
maximal antifibrotic benefit from RAS blockade requires
higher doses than are needed to normalize blood pres-
sure. Titrating ACE inhibitors or AT1 receptor blockers
solely based on their blood pressure lowering effect ac-
cording to currently usual practice is clearly inadequate
to satisfactorily block the local RAS. Despite maximal
blood pressure lowering, a high enalapril dose which had
caused maximal lowering of blood pressure failed to re-
duce, let alone abrogate, intrarenal Ang II concentration
[24]. In the case of AT1 receptor blockade one could spec-
ulate that the reduction in blood pressure induced by AT1
receptor blockers is due not only to an inhibition of AT1
but also to an activation of AT2 as a result of high ambi-
ent levels of Ang II. Thus, a significant reduction in blood
pressure could occur even without a total blockade of AT1
receptors.
In a small study with 16 patients, Agarwal [80] found
that add-on therapy with losartan on a background of
maximal ACE inhibitor treatment leads to a significant
lowering of urinary TGF-b excretion. This effect was in-
dependent of changes in proteinuria and blood pressure
values as determined by 24-hour ambulatory measure-
ments [80]. Since urinary TGF-b excretion presumably
reflects renal synthesis, combination therapy appears to
be significantly more potent in suppressing renal produc-
tion of this important profibrogenic cytokine.
The situation has completely changed with one recent
study assessing the effect of combination therapy on a
hard end point (i.e., end-stage renal failure or doubling
of serum creatinine concentration). In a randomized con-
trolled trial the doses of the ACE inhibitor trandolapril
and the AT1 receptor blocker losartan were carefully ad-
justed to reach absolutely identical blood pressure val-
ues in all treatment arms (i.e., trandolapril, losartan, or
their combination) [90]. Nakao et al [90] showed that a
combination of trandolapril and losartan reduced pro-
gression more effectively than the respective monother-
apies. The risk of reaching the combined end point was
reduced in the combination therapy group by approxi-
mately 50% compared to the respective monotherapies.
There was no difference between the trandolapril and
losartan monotherapies in reaching the end points [90].
Although office measured blood pressures were not dif-
ferent among the various, 24-hour blood pressure mea-
surements were not performed. Thus, its seems possible,
but unlikely, that a better control of night time blood pres-
sure or a different distribution of dippers and non-dippers
in the various groups may explain the superiority of dual
blockade. Since office blood pressure measurements were
performed 15 minutes before administration of the drugs,
it remains unclear whether the blood pressure values
were different at the times of peak actions of the drugs
[90]. Although the theoretical argument whether the ef-
fects of ACE inhibition and AT1 receptor blockade are
additive is not definitely answered, by this study, it never-
theless clearly proves that despite similar blood pressure
control the combination of the maximally licensed doses
of ACE inhibitor and AT1 receptor blocker provides fur-
ther benefit not only on proteinuria, but also on hard end
points. Combination therapy caused more pronounced
lowering in proteinuria and this observation points to a
potential mechanism of action.
ARE THERE POTENTIAL MECHANISMS TO
EXPLAIN THE SUPERIORITY OF
COMBINATION THERAPY?
Azizi et al [105] studied combination therapy in nor-
motensive volunteers with mild sodium depletion, and
proposed the hypothesis that the combination abrogates
the potentially adverse consequences of persistently high
Ang II concentrations during ACE inhibition. Other po-
tential mechanisms to explain the superiority of combina-
tion therapy are summarized in Table 3. Nishiyama, Seth,
and Navar [24] convincingly demonstrated that the com-
ponents of the tissue specific RAS are compartmental-
ized. In animal experiments tissue ACE, including ACE
in the kidney, is not inhibited by the plasma concentra-
tions of ACE inhibitors that are achieved with currently
used doses [24]. Consequently, renal Ang II formation
presumably continues despite blockade of the systemic
RAS by ACE inhibitors in doses which achieve maximal
lowering of blood pressure. Furthermore, alternative en-
zymes which are not inhibited by ACE inhibitors such as
chymase [40] and other serine proteases might still lead
to significant local Ang II concentrations within the kid-
ney even when one would achieve complete inhibition of
the local ACE [37]. Experimental studies have demon-
strated that a compensatory Ang II release during ACE
inhibition occurs exclusively from within the kidney, in-
dicating that intrarenal non-ACE–dependent pathways
of Ang II formation are stimulated [106]. Since AT1 re-
ceptor blockers increase the concentration of Ang II, it is
conceivable that, at least at low concentrations of Ang II
receptor blockers, high Ang II concentrations may over-
come inhibition of the AT1 receptor. Furthermore, the
increased availability of Ang II will increase the gener-
ation of Ang IV that binds to a separate receptor and
mediates, at least in experimental settings, profibrogenic
effects that are not antagonized by AT1 receptor block-
ers [59, 60]. We have shown that aminopeptidases in the
kidney which are responsible for Ang IV formation are
up-regulated in situations with high local Ang II and/or
renal injury [56]. In animals fed a low-salt diet to activate
the RAS, combination therapy with ACE inhibitor and
AT1 receptor blocker reduced renal tissue Ang II con-
centrations more than higher doses of either agent alone
[107].
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Table 3. Potential mechanisms why combination therapy could be superior to the respective monotherapies
Angiotensin-converting enzyme (ACE) inhibitors
Shortcomings
Ongoing angiotensin II generation by ACE independent enzymes (chymase)
Failure to block the compartmentalized intrarenal ACE
Inhibition of angiotensin 1-7 formation that partly antagonizes effects of angiotensin II
Advantages
Feedback inhibition of renin release by angiotensin II relatively maintained
Less angiotensin II available to stimulate angiotensin II type 2 (AT2) receptors if one assumes that stimulation causes negative effects
Direct protective effect of ACE inhibitors independent of renin-angiotensin system?
AT1 receptor blocker
Shortcomings
High angiotensin II concentrations because of interruption of negative feedback
High renin (interruption of negative feedback) that may bind to specific renin receptors
Stimulation by Angiotensin II of AT2 receptors with activation of pathophysiologic pathways [apoptosis, nuclear factor-kappaB (NF-jB)
activation, induction of chemokines]
Metabolism of angiotensin II through local peptidases into other peptides, including angiotensin IV, which binds to specific receptors not
blocked by AT1 receptor antagonists
Since angiotensin II binds to AT2 receptors, which may transduce vasodilatory effects, in the presence of AT1 receptor antagonists, titration
of the drug according to blood pressure may lead to incomplete AT1 receptor blockade
Advantages
Complete blockade of AT1 receptor-mediated effects
Vasodilatation by stimulation of AT2 receptors
No aldosterone escape
A further possibility is binding of Ang II to unoccupied
AT2 receptors during blockade of the AT1 receptor. This
may not be only beneficial as had been widely assumed
[108]. It is true that in AT1A receptor knockout mice less
renal fibrosis is seen when the animals are exposed to
renal injury [109]. Nevertheless, since apoptosis could be
mediated through the AT2 receptors, it is hard to imagine
that an increase in programmed cell death of renal cells
should be protective [47]. Moreover, experimental stud-
ies show that the NF-jB signal transduction pathways are
activated through the AT2 receptor. Infusion of Ang II in
rats leads to glomerular regulated upon activation, nor-
mal T-cell expressed and secreted (RANTES) expression
and influx of macrophages/monocytes [48–50]. These ef-
fects are attenuated in the presence of an AT2 receptor
antagonist. AT2 receptor blockade was also beneficial in
a renal ablation model [51].
Using double-transgenic rats harboring human renin
and angiotensinogen genes, Mervaala et al [110] showed
an additional effect of combination therapy on sodium
handling. In these rats the pressure natriuresis curve is
shifted to the right, indicating that a higher blood pres-
sure is necessary for sodium excretion. ACE inhibition
increased GFR and renal blood flow, but had no signifi-
cant effects on fractional sodium or water reabsorption.
In contrast, AT1 receptor blockade shifted the curves
for fractional sodium and water reabsorption to the left,
but had only small effects on renal blood flow and GFR
[110]. A combination of ACE inhibition and AT1 re-
ceptor blockade had an additive effect and shifted the
pressure-natriuresis curves leftward more than did either
drug alone [110].
Aldosterone exerts directs effects on renal cells in-
dependent of Ang II that may contribute to progres-
sion of renal disease [111]. It is therefore important
that plasma aldosterone increases after long-term ACE
inhibitor treatment. This phenomenon of “aldosterone
escape” is presumably caused by non ACE–dependent
Aang II formation with subsequent induction of aldos-
terone synthesis [112]. In this context it is of interest
that a certain proportion of proteinuric patients with
type 2 diabetes who had been treated with an ACE
inhibitor had a secondary increase in aldosterone (aldos-
terone escape). Additional administration of spironolac-
tone reduced proteinuria in these patients [113]. Whether
further addition of spironolactone or eplerenone will pro-
vide further benefit in patients in whom proteinuria is
not satisfactorily lowered by combination therapy and
whether this treatment is safe will require further studies.
Finally, it is important to pay attention to some pharma-
cokinetic mechanisms. The normal dosing schedule used
in patients is twice daily administration of ACE inhibitors
with intermediate half life (such as enalapril) or of AT1
receptor antagonists (such as losartan). It is questionable
whether this regimen guarantees that plateau effects are
maintained around the clock. In renal insufficiency the
pharmacokinetics are altered, however, and the half life
is considerably longer.
IS COMBINATION THERAPY RISKY?
Clinical observations suggest a link between admin-
istration of ACE inhibitors and worsening of ane-
mia, in patients with chronic renal insufficiency [114–
116]. Ang II stimulates erythropoesis through different
mechanisms. Ang II induces proliferation of erythroid
progenitors by reducing the peptide N-acetyl-seryl-
aspartyl-lysyl-proline (acetyl-SDKP), a possible stem cell
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suppressor (for review see [115]). Through AT2 receptors
Ang II down-regulates SM-20, a dioxygenase responsi-
ble for prolyl hydroxylation of hypoxia-inducible factor
1 (HIF-1) [117]. HIF-1 is an important transcription fac-
tor for erythropoetin. Hydroxylation of HIF-1 targets this
factor into a degradation pathway. Thus, hydroxylation of
HIF-1a results presumably in accelerated degradation in
the absence of Ang II with suppression of erythropoetin
gene transcription. Iodice et al [91] observed a signifi-
cant decrease of hemoglobin concentrations in patients
treated with the combination of 20 mg ramipril/300 mg
irbesartan per day compared to irbesartan alone. How-
ever, this effect was likely caused by the relatively high
dose of the ACE inhibitor because 20 mg ramipril/day
induced a similar degree of anemia [91].
Adverse effects of a combination therapy were ad-
dressed in the study by Ruilope et al [76]. Serum potas-
sium concentration was significantly higher in patients
on combination therapy compared to patients on an
AT1 receptor antagonist alone [76]. This study, unfortu-
nately, did not contain an ACE inhibitor monotherapy
arm. Other trials, however, found a similar frequency of
hyperkalemia in patients on combination therapy com-
pared with ACE inhibitor monotherapy [90]. It is known
that the increase in serum potassium is less marked with
AT1 receptor antagonists than with ACE inhibitors [118].
Therefore, hyperkalemia in the presence of combination
therapy appears to be mainly determined by the ACE in-
hibitor, but the situation may be different in patients with
renal failure. Nevertheless, the incidence of hyperkalemia
in the COOPERATE study was 7.9% in the combination
therapy group, 9.3% in the trandolapril groups, and 4.4%
in the losartan group [90]. Therefore, patients should be
regularly monitored for hyperkalemia and coadministra-
tion of medication that could increase potassium such
as nonsteroidal anti-inflammatory drugs (NSAIDs) or
spironolactone should be avoided. Further observational
studies are necessary to define the rate of hyperkalemia
outside the well-monitored prospective COOPERATE
study with a selected population of patients.
CONCLUSION
According to Sackett et al [119] evidence-based
medicine is “the conscientious, explicit and judicious use
of current best evidence in making decisions about the
care of the individual patient. It means integrating indi-
vidual clinical expertise with the best available external
clinical evidence from systematic research.” Is the cur-
rent evidence enough to treat every patient with chronic
renal insufficiency with combination therapy? We don’t
think so. Although intriguing on the basis of pathophysi-
ologic considerations, only one large trial has so far docu-
mented a convincing effect of the combination therapy on
hard end points [90]. Certainly, more studies in different
ethnic populations and a different spectrum of renal dis-
eases are necessary to confirm these findings from Japan.
This is particularly true for the COOPERATE study
that excluded diabetic patients and it is currently unclear
whether similar effects of combination therapy would
be equally effective in patients with diabetic nephropa-
thy. AT1 receptor antagonists are currently expensive
drugs. Not to the least because of financial considera-
tions, administration of combination therapy should be
reserved currently to special high-risk groups. A recent
meta-analysis revealed that in patients with urine protein
excretion greater than 1 g/day the risk of progression of
renal disease increased steeply with the systolic blood
pressure [120]. In patients on monotherapy despite op-
timal blood pressure control in whom proteinuria does
not decrease to values <1 g/day, the risk of progression is
very high. We think it is plausible to assume that such pa-
tients would derive particular benefit from combination
therapy. The beneficial effect of combination therapy has
to be weighed against the risk of hyperkalemia and fur-
ther studies are necessary to obtain data regarding the
incidence of hyperkalemia under combination therapy,
particularly in patients such as diabetics. Before one rec-
ommends more widespread use of combination therapy,
however, we have to wait for the results of additional
clinical trials. We admit that the demonstration of the su-
periority of combination therapy is intellectually exciting
and pathophysiologically plausible. If further evidence
is generated, it may some day become the treatment of
choice.
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